Advanced

Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia

Abdelnour, Carla; van Steenoven, Inger; Londos, Elisabet LU ; Blanc, Frédéric; Auestad, Bjørn; Kramberger, Milica G.; Zetterberg, Henrik LU ; Mollenhauer, Brit; Boada, Mercè and Aarsland, Dag (2016) In Movement Disorders 31(8). p.1203-1208
Abstract

Introduction: Alzheimer's disease pathologies are common in dementia with Lewy bodies, but their clinical relevance is not clear. CSF biomarkers amyloid beta 1-42, total tau, and tau phosphorylated at threonine 181 reflect Alzheimer's disease neuropathology antemortem. In PD, low CSF amyloid beta 1-42 predict long-term cognitive decline, but little is known about these biomarkers as predictors for cognitive decline in Lewy body dementia. The aim of this study was to assess whether Alzheimer's disease CSF biomarkers predict cognitive decline in Lewy body dementia. Methods: From a large European dementia with Lewy bodies multicenter study, we analyzed baseline Alzheimer's disease CSF biomarkers and serial MMSE (baseline and 1- and 2-year... (More)

Introduction: Alzheimer's disease pathologies are common in dementia with Lewy bodies, but their clinical relevance is not clear. CSF biomarkers amyloid beta 1-42, total tau, and tau phosphorylated at threonine 181 reflect Alzheimer's disease neuropathology antemortem. In PD, low CSF amyloid beta 1-42 predict long-term cognitive decline, but little is known about these biomarkers as predictors for cognitive decline in Lewy body dementia. The aim of this study was to assess whether Alzheimer's disease CSF biomarkers predict cognitive decline in Lewy body dementia. Methods: From a large European dementia with Lewy bodies multicenter study, we analyzed baseline Alzheimer's disease CSF biomarkers and serial MMSE (baseline and 1- and 2-year follow-up) in 100 patients with Lewy body dementia. Linear mixed-effects analyses, adjusted for sex, age, baseline MMSE, and education, were performed to model the association between CSF biomarkers and rate of cognitive decline measured with MMSE. An Alzheimer's disease CSF profile was defined as pathological amyloid beta 1-42 plus pathological total tau or phosphorylated tau. Results: The Alzheimer's disease CSF profile, and pathological levels of amyloid beta 1-42, were associated with a more rapid decline in MMSE (2.2 [P < 0.05] and 2.9 points difference [P < 0.01], respectively). Higher total tau values showed a trend toward association without statistical significance (2.0 points difference; P = 0.064), whereas phosphorylated tau was not associated with decline. Conclusions: Reduced levels of CSF amyloid beta 1-42 were associated with more rapid cognitive decline in Lewy body dementia patients. Future prospective studies should include larger samples, centralized CSF analyses, longer follow-up, and biomarker-pathology correlation.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
cognitive decline, CSF biomarkers, Lewy body dementia
in
Movement Disorders
volume
31
issue
8
pages
6 pages
publisher
John Wiley & Sons
external identifiers
  • scopus:84978394442
  • wos:000382558800021
ISSN
0885-3185
DOI
10.1002/mds.26668
language
English
LU publication?
yes
id
e599cb01-c0d5-4c1a-b2ef-b47cc263ea7d
date added to LUP
2016-12-30 12:21:25
date last changed
2017-09-24 05:05:28
@article{e599cb01-c0d5-4c1a-b2ef-b47cc263ea7d,
  abstract     = {<p>Introduction: Alzheimer's disease pathologies are common in dementia with Lewy bodies, but their clinical relevance is not clear. CSF biomarkers amyloid beta 1-42, total tau, and tau phosphorylated at threonine 181 reflect Alzheimer's disease neuropathology antemortem. In PD, low CSF amyloid beta 1-42 predict long-term cognitive decline, but little is known about these biomarkers as predictors for cognitive decline in Lewy body dementia. The aim of this study was to assess whether Alzheimer's disease CSF biomarkers predict cognitive decline in Lewy body dementia. Methods: From a large European dementia with Lewy bodies multicenter study, we analyzed baseline Alzheimer's disease CSF biomarkers and serial MMSE (baseline and 1- and 2-year follow-up) in 100 patients with Lewy body dementia. Linear mixed-effects analyses, adjusted for sex, age, baseline MMSE, and education, were performed to model the association between CSF biomarkers and rate of cognitive decline measured with MMSE. An Alzheimer's disease CSF profile was defined as pathological amyloid beta 1-42 plus pathological total tau or phosphorylated tau. Results: The Alzheimer's disease CSF profile, and pathological levels of amyloid beta 1-42, were associated with a more rapid decline in MMSE (2.2 [P &lt; 0.05] and 2.9 points difference [P &lt; 0.01], respectively). Higher total tau values showed a trend toward association without statistical significance (2.0 points difference; P = 0.064), whereas phosphorylated tau was not associated with decline. Conclusions: Reduced levels of CSF amyloid beta 1-42 were associated with more rapid cognitive decline in Lewy body dementia patients. Future prospective studies should include larger samples, centralized CSF analyses, longer follow-up, and biomarker-pathology correlation.</p>},
  author       = {Abdelnour, Carla and van Steenoven, Inger and Londos, Elisabet and Blanc, Frédéric and Auestad, Bjørn and Kramberger, Milica G. and Zetterberg, Henrik and Mollenhauer, Brit and Boada, Mercè and Aarsland, Dag},
  issn         = {0885-3185},
  keyword      = {cognitive decline,CSF biomarkers,Lewy body dementia},
  language     = {eng},
  month        = {08},
  number       = {8},
  pages        = {1203--1208},
  publisher    = {John Wiley & Sons},
  series       = {Movement Disorders},
  title        = {Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia},
  url          = {http://dx.doi.org/10.1002/mds.26668},
  volume       = {31},
  year         = {2016},
}